• Home
  •  / Reata Pharmaceuticals

Reata Pharmaceuticals

OverviewSuggest Edit

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases.

Reata focuses on drugs with novel mechanisms of action that modulate important regulatory proteins, called transcription factors, that coordinate the cellular response to stressors by activating or suppressing the activity of many target proteins.

TypePublic
Founded2002
HQPlano, USMap
Websitereatapharma.com
Employee Ratings4More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)220(+79%)
Revenue (FY, 2019)$26.5 M(-44%)
Share Price (May 2020)$147.2 (-3%)

Key People/Management at Reata Pharmaceuticals

Warren Huff

Warren Huff

Founding Chief Executive Officer and President, Director
Dawn C. Bir

Dawn C. Bir

Chief Commercial Officer and Executive Vice President
Colin Meyer

Colin Meyer

Chief Medical Officer and Executive Vice President, Product Development
Manmeet S. Soni

Manmeet S. Soni

Chief Financial Officer and Executive Vice President
Michael D. Wortley

Michael D. Wortley

Chief Legal Officer and Executive Vice President
Jason Wilson

Jason Wilson

Executive Vice President, Operations
Show more

Reata Pharmaceuticals Office Locations

Reata Pharmaceuticals has offices in Plano and Irving
Plano, US (HQ)
5320 Legacy Dr
Irving, US
2801 Gateway Dr #150
Show all (2)

Reata Pharmaceuticals Financials and Metrics

Reata Pharmaceuticals Revenue

Reata Pharmaceuticals's revenue was reported to be $26.52 m in FY, 2019
USD

Revenue (Q1, 2020)

1.4m

Net income (Q1, 2020)

(48.9m)

Market capitalization (28-May-2020)

4.9b

Closing stock price (28-May-2020)

147.2

Cash (31-Mar-2020)

624.5m

EV

4.4b
Reata Pharmaceuticals's current market capitalization is $4.9 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

50.3m49.9m48.1m26.5m

Revenue growth, %

(1%)(4%)

General and administrative expense

13.7m16.6m23.3m32.7m58.3m

R&D expense

35.1m39.5m71.3m97.3m128.1m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

32.4m7.6m5.2m7.8m8.2m1.4m

General and administrative expense

4.5m4.0m5.2m6.0m6.2m6.6m10.7m7.5m10.0m11.7m14.3m20.8m

R&D expense

9.1m9.3m14.6m17.9m18.3m21.4m23.4m27.1m26.1m29.6m32.3m47.7m

Operating expense total

13.8m13.5m19.9m24.0m24.6m28.1m34.2m34.7m36.3m41.3m46.6m68.4m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

42.0m84.7m129.8m337.8m664.3m

Prepaid Expenses

3.3m4.5m5.0m

Inventories

2.6m

Current Assets

77.3m87.3m133.1m342.3m669.3m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

92.4m95.7m82.7m65.2m154.6m105.9m138.7m375.2m313.1m280.4m240.1m624.5m

Prepaid Expenses

2.5m3.3m4.6m4.4m6.8m6.4m5.2m

Current Assets

112.9m99.9m85.7m68.9m157.8m134.7m172.4m379.8m317.5m287.2m246.5m651.9m

PP&E

942.0k899.0k703.0k671.0k774.0k829.0k810.0k795.0k2.7m2.8m2.9m3.9m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(1.4m)(6.2m)(47.7m)(80.5m)(290.2m)

Depreciation and Amortization

1.8m682.0k437.0k431.0k932.0k

Inventories

(1.2m)

Accounts Payable

299.0k(1.8m)2.0m(2.1m)
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(1.2m)(2.1m)(7.1m)(18.7m)(31.0m)4.1m(24.1m)(55.0m)(29.2m)(63.5m)(103.2m)(48.9m)

Depreciation and Amortization

367.0k537.0k130.0k282.0k414.0k101.0k206.0k311.0k170.0k401.0k659.0k278.0k

Accounts Payable

(2.2m)(2.2m)(3.3m)(1.2m)(1.4m)(1.1m)46.0k2.9m(522.0k)312.0k(440.0k)10.7m

Cash From Operating Activities

(11.8m)(8.1m)(22.1m)(39.5m)(58.5m)(24.0m)(49.4m)(46.3m)(28.7m)(61.4m)(101.8m)(41.2m)
show all
USDY, 2020

EV/CFO

-107.5 x

Financial Leverage

2.9 x
Show all financial metrics

Reata Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

240

Patents Pending

280

Phase I Trials Products

2

Phase III Trials Products

1
Show all operating metrics

Reata Pharmaceuticals Revenue Breakdown

Embed Graph

Reata Pharmaceuticals revenue breakdown by business segment: 98.0% from License and Milestone and 2.0% from Other

Reata Pharmaceuticals Online and Social Media Presence

Reata Pharmaceuticals's Trends

Embed Graph

Reata Pharmaceuticals News and Updates

November 14, 2019

Reata Pharmaceuticals, Inc. Announces Pricing of Upsized Class A Common Stock Public Offering

PLANO, Texas, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,400,000 shares of its Class A common stock at a price to the public …
November 12, 2019

Reata Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results and an Update on Development Programs

CONFERENCE CALL WITH MANAGEMENT SCHEDULED FOR TODAY, NOVEMBER 12, 2019 AT 8:00 AM ET CONFERENCE CALL WITH MANAGEMENT SCHEDULED FOR TODAY, NOVEMBER 12, 2019 AT 8:00 AM ET
November 05, 2019

Reata Pharmaceuticals, Inc. to Report Third Quarter 2019 Financial Results and to Provide an Update on Development Programs on November 12, 2019

IRVING, Texas, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs on November 12, 2019, before the marke…
October 11, 2019

Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019

IRVING, Texas, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that three abstracts highlighting clinical and nonclinical data for bardoxolone methyl (bardoxolone) will be presented at the American Society of…
October 10, 2019

Reata Pharmaceuticals Reacquires Rights From AbbVie to Develop and Commercialize Bardoxolone Methyl, Omaveloxolone, and All Next-Generation Nrf2 Activators

IRVING, Texas, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the reacquisition of development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform originall…
June 05, 2019

Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease

IRVING, Texas, June 05, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to bardoxolone methyl (bardoxolone) for the treatment of…
Show more

Reata Pharmaceuticals Blogs

October 14, 2019

Reata Announces Positive Topline Results from the MOXIe Registrational Trial of Omaveloxolone in Patients with Friedreich’s Ataxia

ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN MFARS COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT CONFERENCE CALL WITH MANAGEMENT SCHEDULED FOR OCTOBER 15, 2019 , AT 8:00 AM ET IRVING, Texas , Oct. 14, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc.
August 28, 2019

Reata Appoints Manmeet S. Soni as Chief Financial Officer; Jason D. Wilson to Assume New Role as EVP, Operations

Reata Appoints Manmeet S. Soni as Chief Financial Officer; Jason D. Wilson to Assume New Role as EVP, Operations Content Import Wed, 08/28/2019 - 16:01 Reata Appoints Manmeet S. Soni as Chief Financial Officer; Jason D. Wilson to Assume New Role as EVP, Operations 08/28/19 …
August 08, 2019

Reata Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results and an Update on Development Programs

Conference Call With Management Scheduled for Today, August 8, 2019 IRVING, Texas , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2019 , and provided
August 01, 2019

Reata Second Quarter Financial Results and Update on Development Programs

Reata Second Quarter Financial Results and Update on Development Programs Jonathan.Lorin… Thu, 08/01/2019 - 06:50 Reata Second Quarter Financial Results and Update on Development Programs Display "add to calendar" true Event Type Earnings Confere…
August 01, 2019

Reata Pharmaceuticals, Inc. to Report Second Quarter 2019 Financials and to Provide an Update on Development Programs on August 8, 2019

Reata Pharmaceuticals, Inc. to Report Second Quarter 2019 Financials and to Provide an Update on Development Programs on August 8, 2019 Content Import Thu, 08/01/2019 - 06:45 Reata Pharmaceuticals, Inc. to Report Second Quarter 2019 Financials and to Provide an Update on Development Progra…
February 21, 2019

Reata Fourth Quarter Financial Results and Update on Development Programs

Reata Fourth Quarter Financial Results and Update on Development Programs Jonathan.Lorin… Thu, 02/21/2019 - 07:06 Reata Fourth Quarter Financial Results and Update on Development Programs Display "add to calendar" true Event Type Earnings Confere…
Show more

 Reata Pharmaceuticals Frequently Asked Questions

  • When was Reata Pharmaceuticals founded?

    Reata Pharmaceuticals was founded in 2002.

  • Who are Reata Pharmaceuticals key executives?

    Reata Pharmaceuticals's key executives are Warren Huff, Dawn C. Bir and Colin Meyer.

  • How many employees does Reata Pharmaceuticals have?

    Reata Pharmaceuticals has 220 employees.

  • What is Reata Pharmaceuticals revenue?

    Latest Reata Pharmaceuticals annual revenue is $26.5 m.

  • What is Reata Pharmaceuticals revenue per employee?

    Latest Reata Pharmaceuticals revenue per employee is $120.5 k.

  • Who are Reata Pharmaceuticals competitors?

    Competitors of Reata Pharmaceuticals include AbbVie, MyoKardia and Otonomy.

  • Where is Reata Pharmaceuticals headquarters?

    Reata Pharmaceuticals headquarters is located at 5320 Legacy Dr, Plano.

  • Where are Reata Pharmaceuticals offices?

    Reata Pharmaceuticals has offices in Plano and Irving.

  • How many offices does Reata Pharmaceuticals have?

    Reata Pharmaceuticals has 2 offices.